Friday, Merck & Co Inc (NYSE:MRK) announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, of Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for newly diagnosed patients with high-risk locally advanced cervical cancer.
At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, Keytruda, combined with concurrent CRT, showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
The U.S. pharma giant says Keytruda ...